Market chatter still high on InterMune takeout rumors

Market buzz remains high about several pharmaceutical companies' interest in the orphan drug maker.

InterMune (ITMN) considered selling itself three years ago but no deals were reached due to uncertainty with pirfenidone data.

On February 25, the company disclosed positive trial data showing significant slowing of disease progression versus placebo. Shares gapped up 170% on a 17-fold increase in volume.

Shares are up 14% on heavy volume in today's trading.

250 mutual funds have positions.

From other sites
Comments (1)
  • atosh12
    , contributor
    Comments (25) | Send Message
    It looks like there is lot of speculative money driving this stock. One needs to keep in mind that a clearer picture would appear in May when both ITMN and the competitor present their complete data. Right now, it appears that has been priced in. It is interesting that this piece of news came in just when the momentum in the stock was waning.
    9 Mar 2014, 05:43 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs